Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2005-02-01
2005-02-01
Killos, Paul J. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C560S041000, C562S492000, C564S169000
Reexamination Certificate
active
06849757
ABSTRACT:
Compounds having Formula Ior pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.
REFERENCES:
patent: 4147802 (1979-04-01), Cook et al.
patent: 4251531 (1981-02-01), Doria et al.
patent: 4540689 (1985-09-01), Muto
patent: 5446062 (1995-08-01), Dellaria
patent: 5453533 (1995-09-01), Luo
patent: 5703199 (1997-12-01), Henze
patent: 5741926 (1998-04-01), Bierer
patent: 5869665 (1999-02-01), Padia
patent: 2654215 (1977-06-01), None
patent: 0183271 (1986-06-01), None
patent: 1498996 (1978-01-01), None
patent: 9119980 (1991-12-01), None
patent: 9404156 (1994-03-01), None
patent: 9723500 (1997-07-01), None
patent: 9741824 (1997-11-01), None
patent: 9961406 (1999-12-01), None
Chem. Abst. 127:259879 (1997).*
Chem Abst 95:80296 (1980).*
Teno, et al., “Development of Selective Inhibitors Against Plasma Kallikrein”,Chemical and Pharmaceutical Bulletin, vol. 39(11), pp. 2930-2936 (1991).
Goker, et al. “Synthesis and Antiaggregator Activity of Some New Derivatives of 4H-1-Benzopyran-4-one”,European Journal of Medicinal Chemisty, vol. 30, pp. 561-567 (1995).
Kwon, et al., “Synthesis and Biological Activity of Cinnamaledeyhdes as Angiogenesis Inhibitors”,Bioorganic&Medicinal Chemistry Letters, vol. 7(19), pp. 2473-2476 (1997).
Marui, et al., “Chemical Modifications of Fumagillin. II”,Chemical and Pharmaceutical Bulletin, vol. 40(3), pp. 575-579 (1992).
Craig Richard A.
Henkin Jack
Kawai Megumi
Sheppard George S.
Abbott Laboratories
Corbin Johanna M.
Killos Paul J.
LandOfFree
Antiangiogenic drug to treat cancer, arthritis and retinopathy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiangiogenic drug to treat cancer, arthritis and retinopathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiangiogenic drug to treat cancer, arthritis and retinopathy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3449822